BIOEX Stock Overview
Develops and commercializes a bio-based extraction platform technology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bioextrax AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.32 |
| 52 Week High | SEK 4.50 |
| 52 Week Low | SEK 1.54 |
| Beta | 2.67 |
| 11 Month Change | -6.74% |
| 3 Month Change | -14.87% |
| 1 Year Change | 5.56% |
| 33 Year Change | -95.22% |
| 5 Year Change | n/a |
| Change since IPO | -17.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOEX | SE Machinery | SE Market | |
|---|---|---|---|
| 7D | -5.1% | -2.2% | -2.4% |
| 1Y | 5.6% | 8.2% | 10.9% |
Return vs Industry: BIOEX underperformed the Swedish Machinery industry which returned 7.1% over the past year.
Return vs Market: BIOEX underperformed the Swedish Market which returned 10.8% over the past year.
Price Volatility
| BIOEX volatility | |
|---|---|
| BIOEX Average Weekly Movement | 5.9% |
| Machinery Industry Average Movement | 5.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: BIOEX has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: BIOEX's weekly volatility has decreased from 13% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 13 | Edvard Hall | www.bioextrax.com |
Bioextrax AB (publ) develops and commercializes a bio-based extraction platform technology. It harvests bioplastics (PHA) granules, organic hydrolyzed protein, keratin fibers, bio-oils, protein-rich by products, and amino acids from bacteria. The company was incorporated in 2014 and is based in Lund, Sweden.
Bioextrax AB (publ) Fundamentals Summary
| BIOEX fundamental statistics | |
|---|---|
| Market cap | SEK 116.42m |
| Earnings (TTM) | -SEK 21.41m |
| Revenue (TTM) | SEK 1.56m |
74.8x
P/S Ratio-5.4x
P/E RatioIs BIOEX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOEX income statement (TTM) | |
|---|---|
| Revenue | SEK 1.56m |
| Cost of Revenue | SEK 1.36m |
| Gross Profit | SEK 199.00k |
| Other Expenses | SEK 21.61m |
| Earnings | -SEK 21.41m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.61 |
| Gross Margin | 12.79% |
| Net Profit Margin | -1,376.29% |
| Debt/Equity Ratio | 0% |
How did BIOEX perform over the long term?
See historical performance and comparison